Holen Sie sich die Stockscreener-App
46.28
4.29%
1.865
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Exelixis, Inc. (NASDAQ:EXEL) Q1 2026 Earnings Call Transcript - Insider Monkey
Margin Gains From Oncology Portfolio Might Change The Case For Investing In Exelixis (EXEL) - simplywall.st
Exelixis, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Exelixis Q1 2026 slides: revenue grows 10%, zanzalintinib advances - Investing.com
Exelixis Q1 Earnings Call Highlights - Yahoo Finance
Transcript : Exelixis, Inc., Q1 2026 Earnings Call, May 05, 2026 - marketscreener.com
Exelixis (EXEL) Q1 2026 Earnings Transcript - AOL.com
Earnings call transcript: Exelixis beats Q1 2026 forecasts, stock rises - Investing.com
Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Exelixis Posts Strong Q1 Results, Expands Share Buybacks - TipRanks
Exelixis (EXEL) Tops Q1 Earnings Estimates - Yahoo Finance
Exelixis Beats Q1 Estimates and Advances Pipeline, Driving EXEL Momentum - ChartMill
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B$2.63B, vs. FactSet Est of $2.58B - marketscreener.com
Exelixis Q1 Non-GAAP Earnings, Revenue Rise - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Reports Q1 Revenue $610.8M, vs. FactSet Est of $607.5M - marketscreener.com
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, vs. FactSet Est of $0.76 - marketscreener.com
Exelixis: Q1 Earnings Snapshot - kare11.com
Exelixis (NASDAQ: EXEL) boosts Q1 2026 earnings, cash and buybacks - Stock Titan
Earnings Flash (EXEL) Exelixis, Inc. Posts Q1 Adjusted EPS $0.87 per Share, Vs. FactSet Est of $0.76 - Moomoo
Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - The Joplin Globe
Exelixis earnings on deck: Can RCC franchise weather competition? By Investing.com - Investing.com India
Exelixis earnings on deck: Can RCC franchise weather competition? - Investing.com
MSN Money - MSN
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis to Release First Quarter 2026 Financial Results on Tuesday, May 5, 2026 - Caledonian Record
Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative - Yahoo Finance
Behavioral Patterns of EXEL and Institutional Flows - Stock Traders Daily
Earnings Preview: Exelixis to Report Financial Results Post-market on May 05 - Moomoo
Vanguard Capital Management (NASDAQ: EXEL) reports 5.09% stake - Stock Titan
Exelixis (EXEL) is a top-ranked value stock: Should you buy? - MSN
Exelixis Inc (NASDAQ:EXEL) Passes the Caviar Cruise Quality Screen with Zero Debt and 54% ROIC - ChartMill
Will Exelixis (EXEL) beat estimates again in its next earnings report? - MSN
Exelixis Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance
Why Exelixis (EXEL) is a top value stock for the long term - MSN
Do Options Traders Know Something About Exelixis Stock We Don't? - msn.com
Exelixis, Inc. (EXEL) Stock Analysis: Strong Revenue Growth and Promising Analyst Ratings Spark Investor Interest - DirectorsTalk Interviews
EXEL Technical Analysis | Trend, Signals & Chart Patterns | EXELIXIS INC (NASDAQ:EXEL) - ChartMill
Exelixis jumps on phase 3 data for zanzalintinib in colorectal cancer - MSN
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Community Health (CYH) - The Globe and Mail
Goldman Sachs Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $50 - Moomoo
Exelixis Inc (BSP:E2XE34) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Exelixis (BSP:E2XE34) Cyclically Adjusted PS Ratio : (As of Apr. 27, 2026) - GuruFocus
BSP:E2XE34 ROE %: 45.26% — 110% Above Median - GuruFocus
Exelixis Inc at Piper Sandler Healthcare Conference (Virtual)Pre-recorded Fireside Chat Transcript - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price & 30 Year Financial Data - GuruFocus
Who's Buying or Selling Exelixis Inc (BSP:E2XE34) Stock Today? - GuruFocus
Exelixis (BSP:E2XE34) Shiller PE Ratio : (As of Apr. 27, 2026) - GuruFocus
Exelixis Inc (BSP:E2XE34) Dividend - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock Price, Trades & News - GuruFocus
Exelixis Inc (BSP:E2XE34)Valuation Measures & Financial Statistics - GuruFocus
Exelixis Inc Stock Baskets | BSP:E2XE34 - GuruFocus
Exelixis Inc Stock Operating Data - GuruFocus
Exelixis Inc Stock Warning Signs - GuruFocus
Exelixis Inc (BSP:E2XE34) Competitors 2026 - GuruFocus
Exelixis Inc (BSP:E2XE34) Stock News, Headlines & Updates - GuruFocus
Does Exelixis (EXEL) Gain Quiet Competitive Leverage From a Rival’s Kidney Cancer Setback? - Sahm
EXEL Financials: Income Statement, Balance Sheet & Cash Flow | Exelixis Inc - Stock Titan
RBC Capital reiterates Exelixis stock rating on competitive position By Investing.com - Investing.com Australia
Why Is Merck Stock Falling Tuesday? - Benzinga
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):